https://clinicaltrials.gov/study/NCT04986423

Study Completion Date: 2025-06

Reference: Latest MD&A

"We and our partner Newsoara initiated a 200 patient Phase 2b randomized trial in September 2021 to further evaluate the efficacy and tolerability of the combination of ZEN-3694+ enzalutamide vs. single agent enzalutamide. Newsoara is funding this trial and Astellas is supplying enzalutamide for the trial. To date, this study has accrued approximately 145 patients."

Koo